A15 EFFICACY AND SAFETY OF FILGOTINIB AS INDUCTION THERAPY FOR PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 2B/3 SELECTION STUDY
Sign Up to like & getrecommendations! Published in 2021 at "Gastroenterology"
DOI: 10.1093/jcag/gwab002.014
Abstract: The SELECTION (NCT02914522) Induction Studies evaluated the efficacy/safety of filgotinib (FIL), a preferential JAK1 inhibitor, as induction therapy for patients (pts) with moderately to severely active ulcerative colitis (UC) who were biologic-naïve but failed conventional… read more here.
Keywords: study; induction; moderately severely; remission ... See more keywords
The impact of prehospital time intervals on mortality in moderately and severely injured patients
Sign Up to like & getrecommendations! Published in 2021 at "Journal of Trauma and Acute Care Surgery"
DOI: 10.1097/ta.0000000000003380
Abstract: Supplemental digital content is available in the text. BACKGROUND Modern trauma systems and emergency medical services aim to reduce prehospital time intervals to achieve optimal outcomes. However, current literature remains inconclusive on the relationship between… read more here.
Keywords: time; prehospital time; moderately severely; hour ... See more keywords
Psychometric properties of morning joint stiffness duration and severity measures in patients with moderately to severely active rheumatoid arthritis
Sign Up to like & getrecommendations! Published in 2017 at "Health and Quality of Life Outcomes"
DOI: 10.1186/s12955-017-0813-7
Abstract: BackgroundTo assess the measurement properties of two single-item patient-reported outcome (PRO) measures that assessed the length of time (in minutes) and severity of morning joint stiffness (MJS) experienced each day.MethodsData from two Phase 3, randomized… read more here.
Keywords: severity mjs; severely active; duration; mjs ... See more keywords
Clinical Evaluation of Upadacitinib in the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (UC): Patient Selection and Reported Outcomes
Sign Up to like & getrecommendations! Published in 2023 at "Clinical and Experimental Gastroenterology"
DOI: 10.2147/ceg.s367086
Abstract: Abstract This review addresses appropriate patient selection for upadacitinib, a Janus kinase inhibitor approved by the FDA and EMA for treatment of moderately to severely active ulcerative colitis (UC). Janus kinase molecules can contribute to the… read more here.
Keywords: patient selection; active ulcerative; severely active; ulcerative colitis ... See more keywords